Development and validation of a LC/MS/MS method for 6-keto PGF1α, a metabolite of prostacyclin (PGI2)

Journal of Pharmaceutical and Biomedical Analysis

Volumn 56, Issue 3, 2011, Pages 600-603

  Chappell, Derek L ^a   Xiao, Xiaoyao ^a   Radziszewski, Waldemar ^a   Laterza, Omar F ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

2,3 Dinor 6 keto PGF10; 6 Keto PGF1 ; Analytical validation; LC MS MS; Prostacyclin; Vasorelaxation

Indexed keywords

2,3 DINOR 6 OXOPROSTAGLANDIN F1 ALPHA; 6 OXOPROSTAGLANDIN F1 ALPHA; CREATININE; PROSTACYCLIN;

ADULT; ARTICLE; BLOOD SAMPLING; CREATININE BLOOD LEVEL; CREATININE URINE LEVEL; HUMAN; HUMAN EXPERIMENT; IMMUNOAFFINITY CHROMATOGRAPHY; IN VIVO STUDY; LIQUID CHROMATOGRAPHY; LIQUID CHROMATOGRAPHY TANDEM MASS SPECTROMETRY; MALE; MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; SENSITIVITY AND SPECIFICITY;

6-KETOPROSTAGLANDIN F1 ALPHA; ADOLESCENT; ADULT; CALIBRATION; CHROMATOGRAPHY, LIQUID; CREATININE; EPOPROSTENOL; HUMANS; MALE; MIDDLE AGED; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; TANDEM MASS SPECTROMETRY; URINE SPECIMEN COLLECTION; YOUNG ADULT;

EID: 79961127056     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2011.06.019     Document Type: Article

References (10)

1. Gryglewski R.J. Prostacyclin among prostanoids. Pharmacol. Rep. 2008, 60:3-11.
2. Flavahan N.A. Balancing prostanoid activity in the human vascular system. Trends Pharmacol. Sci. 2007, 28:106-110.
3. FitzGerald G.A., Brash A.R., Falardeau P., Oates J.A. Estimated rate of prostacyclin secretion into the circulation of normal man. J. Clin. Invest. 1981, 68:1272-1276.
4. Bucher M., Kees F.K., Messmann B., Lunz D., Rath S., Zelenka M., Schlitt H.J., Hobbhahn J. Prostaglandin I2 release following mesenteric traction during abdominal surgery is mediated by cyclooxygenase-1. Eur. J. Pharmacol. 2006, 536:296-300.
5. Schramm W., Smith R.H., Jackson T.M., Craig P.A., Grates H.E., Minton L.L. Rapid solid-phase immunoassay for 6-keto prostaglandin F1 alpha on microplates. Clin. Chem. 1990, 36:509-514.
6. Serebruany V., Malinin A., Qiu F.H., Xu X.C., Kunsch C., Scott R. Selective thromboxane inhibition after vascular protectant AGI-1067: results of assessment of lipoprotein profiles (ALPS) biomarkers in vitro and in vivo substudy. J. Thromb. Thrombolysis 2009, 27:438-446.
7. Schwartz J.I., Dallob A.L., Larson P.J., Laterza O.F., Miller J., Royalty J., Snyder K.M., Chappell D.L., Hilliard D.A., Flynn M.E., Cavanaugh P.F., Wagner J.A. Comparative inhibitory activity of etoricoxib, celecoxib, and diclofenac on COX-2 versus COX-1 in healthy subjects. J. Clin. Pharmacol. 2008, 48:745-754.
8. Patrono C., Dunn M.J. The clinical significance of inhibition of renal prostaglandin synthesis. Kidney Int. 1987, 32:1-12.
9. Rosenkranz B., Fischer C., Reimann I., Weimer K.E., Beck G., Frolich J.C. Metabolism of prostacyclin and 6-keto-prostaglandin F1 alpha in man. Artery 1980, 8:18-22.
10. Van Hecken A., Schwartz J.I., Depre M., De Lepeleire I., Dallob A., Tanaka W., Wynants K., Buntinx A., Arnout J., Wong P.H., Ebel D.L., Gertz B.J., De Schepper P.J. Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J. Clin. Pharmacol. 2000, 40:1109-1120.